A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis (MERAK)

Capital Medical University

Status and phase: Completed; Phase 2

Conditions: Allergic Rhinitis

Treatments: Biological: Interleukin-4 receptor responders 2; Biological: Placebo; Biological: Interleukin-4 receptor responders 1

Study type: Interventional

Funder types: Other

Identifiers

NCT05470647

CM310_IIS_SAR05

Details and patient eligibility

About

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Full description

AR is a common clinical chronic nasal disease, affecting 10% to 20% of the world's population, and has become a global health problem. AR not only seriously affects the quality of life of patients, resulting in patient fatigue, impaired learning, attention, and decision-making ability, but also causes a heavy social burden.

AR has a variety of classification methods. According to the type of allergen, it can be divided into seasonal (SAR, common allergens are seasonal allergens such as pollen) and perennial (PAR, common allergens are indoor allergens such as dust mites or occupational allergies), which is a classification method often used in clinical studies. According to the course of the disease, it can be divided into intermittent (symptom onset < 4 days/week, or < 4 consecutive weeks) and persistent (symptom onset ≥ 4 days/week, and ≥ 4 consecutive weeks). According to the severity of the disease, it can be divided into minor AR (mild symptoms, with no significant impact on quality of life) and moderate-severe AR (more severe or severe symptoms, with significant impact on quality of life). The results of the cooperative survey showed that persistent moderate-to-severe disease was the most common in the overall population, accounting for 52.2%, indicating that the treatment and control of AR has become an urgent problem to be solved.

Enrollment: 93 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Voluntarily sign the informed consent form.

Exclusion criteria

• Have any condition that are not suitable for participating in this study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

93 participants in 3 patient groups, including a placebo group

Interleukin-4 receptor responders 1

Experimental group

Description:

Interleukin-4 receptor was injected subcutaneously, once every two weeks.

Treatment:

Biological: Interleukin-4 receptor responders 1

Interleukin-4 receptor responders 2

Experimental group

Description:

Interleukin-4 receptor was injected subcutaneously, once a week.

Treatment:

Biological: Interleukin-4 receptor responders 2

Controls

Placebo Comparator group

Description:

Placebo was injected subcutaneously.

Treatment:

Biological: Placebo